BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs.
BioNTech收购了中国抗癌药制造商普米斯生物技术(Biotheus)，交易价值接近10亿美元。这家新冠疫苗研发商拟利用中国在健康科学领域的专长开发有前景的免疫治疗药物。
The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda, the best-selling drug globally in 2023 with $25bn in sales.
这笔交易让这家德国生物技术公司控制一类药物，该类药物已显示出超越默沙东(MSD)重磅抗癌药可瑞达(Keytruda)的潜力，后者是2023年全球最畅销药物，销售额达250亿美元。
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn.
BioNTech将向总部位于广东省的制药商普米斯支付8亿美元预付款，之后支付最高1.5亿美元的里程碑付款。
Uğur Şahin, chief executive of BioNTech, said the company believed that the Biotheus drug “has the potential to set a new standard of care in multiple oncology indications”.
BioNTech首席执行官吴沙忻(Uğur Şahin)表示，该公司相信普米斯研发的药物“有潜力超越传统的检查点抑制剂，在多种肿瘤适应症领域建立新的治疗标准”。